Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00908349 · ClinicalTrials.gov registry record · Phase 3
Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy
A Phase 3 study, sponsored by Supernus Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 214
- Enrollment target
NCT00908349 is a Phase 3 study that has completed, run by Supernus Pharmaceuticals. The registered enrollment target is 214 participants.
The verdict
NCT00908349, a Phase 3 study, has completed, sponsored by Supernus Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 214 participants
- Enrollment target
Study Summary
Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)
Interventions
- DRUG Oxcarbazepine XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 214 participants |
| Start Date | 2009-06 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00908349
The ClinicalTrials.gov registry entry for NCT00908349 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 214 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Supernus Pharmaceuticals, which has 57 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Oxcarbazepine XR is the first listed.
NCT00908349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00908349 about?
NCT00908349 is a clinical study titled "Safety and Tolerability of OXC XR as Adjunctive Therapy in Subjects With Refractory Partial Epilepsy". Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oxcarbazepine Extended-Release (OXC XR)
What is the current status of trial NCT00908349?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 214 participants. The study started on 2009-06. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00908349?
The interventions under investigation include: Oxcarbazepine XR (DRUG).
Who is sponsoring clinical trial NCT00908349?
This trial is sponsored by Supernus Pharmaceuticals, which has 57 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.